Topiramate vs divalproex sodium in the preventive treatment of migraine: A prospective "real-world" study

Headache

Volumn 51, Issue 4, 2011, Pages 554-558

  Krymchantowski, Abouch V ^a   Jevoux, Carla C ^a  

^a Headache Center of Rio   (Brazil)

Author keywords

Divalproex sodium; Migraine; Prophylaxis; Topiramate

Indexed keywords

TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; COGNITIVE DEFECT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MIGRAINE; MORNING DOSAGE; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 79953689282     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01868.x     Document Type: Article

References (23)

1. Scher AI, Stewart WF, Lipton RB. Migraine and headache: A meta-analytic approach. In: Crombie IK, ed. Epidemiology of Pain. Seattle: IASP Press; 1999:159-170.
2. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology. 1994;44(Suppl. 4):24-39.
3. Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of migraine. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain. New York: Oxford University Press; 2001:85-107.
4. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998;38:87-96. (Pubitemid 28155226)
5. Stang PE, Von Korff M. The diagnosis of headache in primary care: Factors in the agreement of clinical and standardized diagnoses. Headache. 1994;34:138-142. (Pubitemid 24129303)
6. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543-552. (Pubitemid 26374327)
7. DeFusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genetics. 2003;33:192-196. (Pubitemid 36177073)
8. Welch KMA, D'Andrea G, Tepley N, Barkeley GL, Ramadan NM. The concept of migraine as a state of central neuronal hyper excitability. Headache. 1990;8:817-828. (Pubitemid 20360045)
9. Welch KMA. Brain hyperexcitability: The basis for antiepileptic drugs in migraine prevention. Headache. 2005;45(Suppl. 1):S25-S32.
10. Cutrer M. Antiepileptic drugs: How they work in headache. Headache. 2001;41(Suppl. 1):S3-S10.
11. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
12. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophyalxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943-950. (Pubitemid 39119312)
13. Silberstein S, Neto W, Schmitt J, et al. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004;61:490-495. (Pubitemid 38923736)
14. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramte 200 mg/day in the prevention of migraine with/without aura in adults: A randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28:1002-1011. (Pubitemid 44380318)
15. Silberstein SD. Divalproex sodium in headache - literature review and clinical guidelines. Headache. 1996;36:547-555. (Pubitemid 26359427)
16. Headache Classification Subcommittee of the International Headache Society. Classification of Headache Disorders, 2nd edn. Cephalalgia. 2004;24:9-150.
17. Krymchantowski AV, Tavares C, Penteado JC, Adriano M. Topiramate in the preventive treatment of migraine: Experience in a tertiary center. Arq Neuropsiquiatr. 2004;62:91-95. (Pubitemid 38489822)
18. Jones MW.Topiramate - safety and tolerability. Can J Neurol Sci. 1998;25:13-15.
19. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48:210-220. (Pubitemid 351178286)
20. D'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic migraine forms and cluster headache:A review of their efficacy and tolerability. Neurol Sci. 2007;28(suppl. 2):S188-S197. (Pubitemid 46813651)
21. Unalp A, Uran N, Oztürk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J Child Neurol. 2008;23:1377-1381.
22. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: A randomized blinded crossover study. Headache. 2006;46:642-648.
23. Nelles G, Schmitt L, Humbert T, et al. TOPMATMIG-0001 investigators. J Headache Pain. 2010;11:33-44.